BOSTON — Two doses of an live-attenuated intranasal COVID-19 vaccine generated a robust immune response, according to phase one data presented at IDWeek. “Live-attenuated virus vaccines are a modality that have been around for decades. The trial that [these data are] from is a first in-human clinical trial that was…Read More
Intranasal COVID19 vaccine candidate generates robust immune response ExBulletin
